Obinutuzumab for the treatment of non-Hodgkin lymphomas

被引：0

作者：

Hernandez, Juana ^{[1
]}

Nielsen, Tina ^{[1
]}

Klein, Christian ^{[1
]}

Wenger, Michael ^{[1
]}

机构：

[1] F Hoffmann La Roche Ltd, Grenzacherstr 124, CH-4070 Basel, Switzerland

来源：

NATURE | 2018年 / 563卷 / 7731期

关键词：

FOLLICULAR LYMPHOMA; RITUXIMAB;

D O I：

暂无

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

引用

页数：3

共 12 条

[1] CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies [J].

Bacac, Marina ;

Colombetti, Sara ;

Herter, Sylvia ;

Sam, Johannes ;

Perro, Mario ;

Chen, Stanford ;

Bianchi, Roberta ;

Richard, Marine ;

Schoenle, Anne ;

Nicolini, Valeria ;

Diggelmann, Sarah ;

Limani, Florian ;

Schlenker, Ramona ;

Husser, Tamara ;

Richter, Wolfgang ;

Bray-French, Katharine ;

Hinton, Heather ;

Giusti, Anna Maria ;

Freimoser-Grundschober, Anne ;

Lariviere, Laurent ;

Neumann, Christiane ;

Klein, Christian ;

Umana, Pablo .

CLINICAL CANCER RESEARCH, 2018, 24 (19) :4785-4797

[2] Interindividual Variability of Response to Rituximab: From Biological Origins to Individualized Therapies [J].

Cartron, Guillaume ;

Trappe, Ralf Ulrich ;

Solal-Celigny, Philippe ;

Hallek, Michael .

CLINICAL CANCER RESEARCH, 2011, 17 (01) :19-30

[3]

Chan WC, 1997, BLOOD, V89, P3909

[4] Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study [J].

Cheson, Bruce D. ;

Chua, Neil ;

Mayer, Jiri ;

Dueck, Greg ;

Trneny, Marek ;

Bouabdallah, Kamal ;

Fowler, Nathan ;

Delwail, Vincent ;

Press, Oliver ;

Salles, Gilles ;

Gribben, John G. ;

Lennard, Anne ;

Lugtenburg, Pieternella J. ;

Fingerle-Rowson, Gunter ;

Mattiello, Federico ;

Knapp, Andrea ;

Sehn, Laurie H. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (22) :2259-+

[5] A tale of two antibodies: obinutuzumab versus rituximab [J].

Freeman, Ciara L. ;

Sehn, Laurie H. .

BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 (01) :29-45

[6] Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions [J].

Goede, Valentin ;

Fischer, Kirsten ;

Busch, Raymonde ;

Engelke, Anja ;

Eichhorst, Barbara ;

Wendtner, Clemens M. ;

Chagorova, Tatiana ;

de la Serna, Javier ;

Dilhuydy, Marie-Sarah ;

Illmer, Thomas ;

Opat, Stephen ;

Owen, Carolyn J. ;

Samoylova, Olga ;

Kreuzer, Karl-Anton ;

Stilgenbauer, Stephan ;

Doehner, Hartmut ;

Langerak, Anton W. ;

Ritgen, Matthias ;

Kneba, Michael ;

Asikanius, Elina ;

Humphrey, Kathryn ;

Wenger, Michael ;

Hallek, Michael .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (12) :1101-1110

[7] Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group [J].

Hiddemann, W ;

Kneba, M ;

Dreyling, M ;

Schmitz, N ;

Lengfelder, E ;

Schmits, R ;

Reiser, M ;

Metzner, B ;

Harder, H ;

Hegewisch-Becker, S ;

Fischer, T ;

Kropff, M ;

Reis, HE ;

Freund, M ;

Wörmann, B ;

Fuchs, R ;

Planker, M ;

Schimke, J ;

Eimermacher, H ;

Trümper, L ;

Aldaoud, A ;

Parwaresch, R ;

Unterhalt, M .

BLOOD, 2005, 106 (12) :3725-3732

[8] Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety [J].

Hiddemann, Wolfgang ;

Barbui, Anna Maria ;

Canales, Miguel A. ;

Cannell, Paul K. ;

Collins, Graham P. ;

Duerig, Jan ;

Forstpointner, Roswitha ;

Herold, Michael ;

Hertzberg, Mark ;

Klanova, Magdalena ;

Radford, John ;

Seymour, John F. ;

Tobinai, Kensei ;

Trotman, Judith ;

Burciu, Alis ;

Fingerle-Rowson, Gunter ;

Wolbers, Marcel ;

Nielsen, Tina ;

Marcus, Robert E. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (23) :2395-+

[9] Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity [J].

Moessner, Ekkehard ;

Bruenker, Peter ;

Moser, Samuel ;

Puentener, Ursula ;

Schmidt, Carla ;

Herter, Sylvia ;

Grau, Roger ;

Gerdes, Christian ;

Nopora, Adam ;

van Puijenbroek, Erwin ;

Ferrara, Claudia ;

Sondermann, Peter ;

Jaeger, Christiane ;

Strein, Pamela ;

Fertig, Georg ;

Friess, Thomas ;

Schuell, Christine ;

Bauer, Sabine ;

Dal Porto, Joseph ;

Del Nagro, Christopher ;

Dabbagh, Karim ;

Dyer, Martin J. S. ;

Poppema, Sibrand ;

Klein, Christian ;

Umana, Pablo .

BLOOD, 2010, 115 (22) :4393-4402

[10] Survival after progression in patients with follicular lymphoma:: analysis of prognostic factors [J].

Montoto, S ;

López-Guillermo, A ;

Ferrer, A ;

Camós, M ;

Alvarez-Larrán, A ;

Bosch, F ;

Bladé, J ;

Cervantes, F ;

Esteve, J ;

Cobo, F ;

Colomer, D ;

Campo, E ;

Montserrat, E .

ANNALS OF ONCOLOGY, 2002, 13 (04) :523-530

← 1 2 →